Competition between domestic pharmaceutical companies has been heating up for the rights to copromote vaccines by multinational pharmaceutical companies. With new products being released one after another in Korea, domestic companies are intent on becoming partners to secure these vaccines that generate stable cash flow.

In fact, over the past 2 years, 6 domestic pharmaceutical companies were found to have been competing to copromote 15 vaccines by 2 multinational pharmaceutical companies. The joint sales partners are showing mixed responses depending on whether they have secured the domestic sales rights for the vaccines.

Eight MSD vaccines will be jointly sold by Boryung Bi

Kim, Jin-Gu(kjg@dailypharm.com)